SRT1720 activates AMPK by directly inhibiting cAMP phosphodiesterases, suggesting that cAMP phosphodiesterases may be potential drug targets for obesity-related diseases. This evidence concerns the gene PRKAA2 and obesity due to melanocortin 4 receptor deficiency.